What Laboratorios ERN does

Laboratorios ERN is a privately held Spanish pharmaceutical laboratory founded in Barcelona in 1942, organized as LABORATORIOS ERN, S.A., with 101-250 employees. The company develops, manufactures, and commercializes prescription and over-the-counter pharmaceutical products across twelve therapeutic areas, with a stated specialization in pediatric formulations and adjacent coverage in dermatology, pain, respiratory, CNS, cardiorespiratory, genitourinary, corticotherapy, oral-pharyngeal health, fluid therapy, gastrointestinal health, and nutritional supplementation. Its core technology is pharmaceutical formulation and manufacturing, including weight-based pediatric dosing systems, palatability-tuned dosage forms, and microparticle technology for respiratory drug delivery incorporated into Luforbec. Operationally, ERN runs owned manufacturing at its Barcelona headquarters plant, a production facility in Barberá del Vallés, and a logistics center in Sant Andreu de la Barca, with a delegation office in Madrid.

The business model combines direct sales to Spanish hospital procurement and pharmacy retail for prescription, OTC, and self-care products with international expansion executed through licensing partnerships. Domestic reach is achieved via enterprise field sales to hospitals and pharmacies; international reach is achieved via partner-led commercialization, exemplified by Meitheal Pharmaceuticals for Contepo (intravenous fosfomycin) in the United States and Lupin Limited for Luforbec in Spain. Revenue streams include branded prescription pharmaceuticals, OTC and self-care, hospital injectables and fluid therapy (Vitulia line), nutritional supplements (Astenolit Infantil, Ernamín), and licensing royalties. Prescription drug pricing in Spain operates under AEMPS reference frameworks; OTC and self-care prices are set at retail; specific unit prices disclosed include Fortecortín 1 mg/30 tablets at €4.34, Fortecortín 4 mg at €9.59, Decentán 8 mg/50 tablets at €3.59, Gelidina 30 g at €3.29, and Vitulia 1000 ml at €2.53 (all IVA included).

Key recent strategic actions include FDA approval of intravenous fosfomycin (October 2025), US commercialization of Contepo via Meitheal (April 2026), Spain launch of Luforbec via Lupin (June 2026), domestic launch of Ernamín for advanced CKD (June 2025), participation in the CDTI-funded ANTISALINA R&D project with Ercros (May 2026), and FEC Silver membership for climate action (2026). The General Manager, David Solanes López, was appointed Academician of the Royal Academy of Pharmacy of Catalonia in October 2025. A CSR-linked sales program donates €1 per unit of Astenolit Infantil sold to pediatric rare disease research at Sant Joan de D\u00e9u Hospital Barcelona.

Name

Laboratorios ERN

Legal name

LABORATORIOS ERN, S.A.

Website

https://ern.es

Company type

Private

Founded year

1942

Operating status

Operating

Headcount range

101–250 employees

Short description

Laboratorios ERN is a privately held Spanish pharmaceutical laboratory founded in 1942 in Barcelona that develops, manufactures, and distributes prescription, OTC, and hospital pharmaceutical products across twelve therapeutic areas, with specialized pediatric formulations, direct hospital and pharmacy sales in Spain, and international licensing partnerships including the United States.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Cold, Flu & Cough Remedies (HLAIADAB), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Pediatric pharmaceutical formulations
• Prescription drug manufacturing
• Fluid therapy solutions
• Respiratory inhaler medicines
• Topical corticosteroid formulations

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals: Revenue from branded and generic prescription medicines across therapeutic areas including pediatrics, dermatology, pain, respiratory, CNS, cardiorrespiratory, genitourinary, and corticotherapy, distributed through pharmacies and hospitals in Spain.
2. Over-the-Counter (OTC) / Self-Care Products: Revenue from non-prescription healthcare products including dermocosmetics, food supplements, personal hygiene, and self-care medical devices sold through pharmacy retail channels.
3. Hospital/Injectable Products: Revenue from hospital-use injectable products including fluid therapy solutions (saline, Ringer's lactate, glucosated serums) and intravenous antibiotics such as fosfomicina intravenosa (Contepo) commercialized in the United States.
4. Licensing & International Partnerships: Revenue generated through international licensing agreements such as the Meitheal Pharmaceuticals partnership for US commercialization of intravenous fosfomycin (Contepo), and strategic alliances like the Lupin Limited agreement for Spain distribution of Luforbec.
5. Nutritional Supplements: Revenue from food supplements including Astenolit Infantil (for pediatric energy and immune support), Ernamín (amino acid and ketoanalogue combination for CKD dietary management), and calcium/potassium supplements.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Laboratorios ERN develops, manufactures, and supplies branded and generic pharmaceutical products across 12 therapeutic areas (pediatrics, dermatology, pain, respiratory, CNS, cardiorespiratory, genitourinary, corticotherapy, oral-pharyngeal, fluid therapy, gastrointestinal, and self-care). Its portfolio spans prescription medicines sold to hospitals and pharmacies, OTC/self-care products, hospital injectables (including IV fosfomycin and saline/Ringer's solutions), and nutritional supplements, with international expansion carried out via licensing partnerships.

Product overview

Laboratorios ERN is a Spanish pharmaceutical laboratory founded in 1942, specializing in the development, manufacturing, and commercialization of prescription and OTC pharmaceutical products across 12 therapeutic areas. The company operates as a multi-product portfolio organization with distinct product lines including: pediatric formulations (with pediatric specialists focus), acute hospital products (antibiotics, fluid therapy), chronic disease treatments (respiratory, CNS, dermatology), and self-care/OTC products. Key brands include Ernamín (renal nutrition), Luforbec® (respiratory), Contepo® (IV antibiotic), Astenolit (pediatric nutrition), Vitulia (fluid therapy), Fortecortín/Dacortín/Astonín (corticosteroids), Gelidina (topical steroids), Decentán/Amantadine (CNS), and oral health products (Afta-Juventus, Sanodin, Lema, Hibitane). The company pursues incremental drug innovation strategy and international expansion through licensing partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• Contepo: Intravenous fosfomycin 6g antibiotic brand commercialized in the United States through partnership with Meitheal Pharmaceuticals
• Luforbec
• Ernamín
• Astenolit Infantil
• Vitulia

Products and services

• Ernamín Nutritional product containing essential amino acids and ketoanalogues used alongside a very low-protein diet to preserve kidney function, improve nutritional status, and delay the need for dialysis in patients with advanced chronic kidney disease.
• Contepo (Fosfomicina intravenosa 6 g) Hospital-use IV antibiotic indicated for complicated urinary tract infections, including acute pyelonephritis, in adults. Commercialized in the United States through a strategic licensing agreement with Meitheal Pharmaceuticals.
• Luforbec (Beclometasona/Formoterol) 100/6 Fixed-dose pressurised metered-dose inhaler combining beclometasone and formoterol for the treatment of asthma in adults and COPD, incorporating microparticle technology that delivers active ingredient to pulmonary alveoli more efficiently at a minimized dose. Distributed in Spain through a strategic alliance with Lupin Limited.
• Astenolit Infantil Nutritional supplement designed to support children's energy levels and immune defenses. Laboratorios ERN donates €1 per unit sold to pediatric rare disease research at Sant Joan de Déu Hospital Barcelona.
• Decentán 8 mg Antipsychotic tablets in packs of 50 for central nervous system (CNS) treatment.
• Amantadine Level 100 mg Hard capsules in packs of 20 used as an antiparkinsonian for the treatment of CNS disorders.
• Vitulia Solutions Line of saline and fluid therapy products including physiological saline, irrigation solutions, Ringer's lactate, glucosaline, and glucose serums (5%, 10%, 20%) supplied in single-dose flasks and hospital multi-packs for IV infusions, nebulizations, wound irrigation, and hospital fluidotherapy.
• Afta-Juventus Gingival solution 30 ml for oral mucosa health including gingivitis and canker sores.
• Sanodin Herpes & Sanodin Hyalo Oral antiseptic products including Sanodin Herpes labial patches (15 units) and Sanodin Hyalo hyaluronic acid oral gel (10 ml) for mucosal health.
• Lema ERN Dental care products including Lema ERN C flask (40 g) and Lema ERN oxygen/fluoride paste (50 ml) for dental hygiene.
• Hibitane & Hibit's Oral antiseptics including Hibitane sucking tablets (20 lemon tablets) and Hibit's sugar-free strawberry lozenges (16 units) for oral-pharyngeal care.
• Gelidina 0.25 mg/g Topical corticosteroid gel available in 30 g and 60 g tubes for dermatological conditions.
• Fortecortín Oral corticosteroid available in 1 mg, 4 mg, and 8 mg tablet formulations (30 tablets per pack) for inflammatory and autoimmune conditions.
• Dacortín Oral corticosteroid available in 2.5 mg, 5 mg, and 30 mg tablet formulations (30 tablets per pack) for systemic anti-inflammatory treatment.
• Astonín 0.1 mg Oral corticosteroid tablets, 40 tablets per package, for systemic mineralocorticoid replacement therapy.

Quantifiable outcome

• Intravenous fosfomycin demonstrated 63.5% global success and clinical cure with microbiological eradication vs. 55.6% for piperacilina/tazobactam in the ZEUS clinical trial (464 hospitalized adults with cUTI).
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Lupin LimitedcoreStrategic or Co-development Partner · 1 June 2026Strategic alliance between Laboratorios ERN and Lupin Limited (global pharmaceutical company headquartered in Mumbai, India with products distributed in 100+ markets) for the launch in Spain of Luforbec® (beclometasone / formoterol) 100/6, a fixed-dose combination in a pressurised metered-dose inhaler (pMDI) for asthma and COPD treatment. Lupin is a world leader in respiratory medicines and pMDI technology. ERN leverages this alliance to strengthen its respiratory portfolio in hospital, primary care, and pharmacy settings. Luforbec incorporates microparticle technology for more efficient pulmonary alveoli delivery with minimized active ingredient dose.
• ErcrosminorStrategic or Co-development Partner · 1 May 2026Laboratorios ERN and Ercros are joint beneficiaries of a public grant from CDTI (Centro para el Desarrollo Tecnológico y la Innovación) under the National Cooperative R&D Programme for the development of the ANTISALINA project. This collaborative R&D initiative focuses on developing new innovative solutions in the field of research and experimental development, reinforcing ERN's commitment to incremental innovation.
• Sant Joan de Déu Hospital BarcelonaminorStrategic or Co-development Partner · 1 January 2026Laboratorios ERN supports research into pediatric rare diseases at Sant Joan de Déu Hospital Barcelona. During 2026, ERN donates €1 per unit sold of Astenolit Infantil (pediatric nutritional supplement for energy and immune support) to benefit rare disease pediatric research. Sant Joan de Déu is one of Europe's most important pediatric centers of high specialization, currently attending to over 28,000 rare disease patients.
• Fundación Empresa y Clima (FEC)minorOthers · 1 January 2026Laboratorios ERN joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing its commitment to climate action and global sustainability. This membership supports the transition toward a low-carbon economy and provides services to strengthen ERN's internal capabilities to manage and reduce greenhouse gas emissions.
• Meitheal PharmaceuticalscoreStrategic or Co-development Partner · 1 October 2025Strategic agreement between Laboratorios ERN and Meitheal Pharmaceuticals (specialist in commercialization of generic and biologic injectable products) for the commercialization of intravenous fosfomycin (Contepo®) in the United States. FDA approved Contepo (fosfomicina intravenosa 6 g) on October 22, 2025 for complicated urinary tract infections. ERN played a key role as promoter in the US for the introduction of this molecule before transferring rights to Meitheal for commercialization. April 2026 marked the commercial launch in the US market.
• CDTI (Centro para el Desarrollo Tecnológico y la Innovación)minorOthersCDTI is a Spanish public entity that provides funding for research and development projects. Laboratorios ERN, together with Ercros, received CDTI funding for the ANTISALINA collaborative R&D project under the National Cooperative R&D Programme.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Almirall: Spanish pharmaceutical company with strong dermatology franchise and specialty pharma positioning. While larger and dermatology-focused, Almirall shares the Spanish-headquartered branded pharma model and recent product launch cadence, including licensing partnerships for international expansion.
• Kern Pharma: Spanish pharmaceutical subsidiary of Grupo Indukern with branded generics, biosimilars, and OTC products. Overlaps with Laboratorios ERN in hospital injectables, respiratory, and OTC categories. Similar mid-market positioning in Spain.
• Reig Jofre: Barcelona-based pharmaceutical company with similar heritage and product portfolio spanning prescription, OTC, and nutritional supplements. Highly comparable in size, geography, and multi-therapeutic branded approach. Strong overlap in target customers and channel mix.
• Laboratorios Salvat: Spanish specialty pharmaceutical company focused on ENT and ophthalmology with branded prescription products. Comparable in size, private ownership, and therapeutic specialization strategy. Both companies serve similar hospital and pharmacy channels in Spain.
• Faes Farma: Spanish pharmaceutical company of similar mid-cap size with branded prescription, OTC, and specialty nutrition products. Most directly comparable to Laboratorios ERN in terms of geographic footprint, business model mix, and therapeutic breadth. Listed on the Spanish stock exchange, providing a useful valuation benchmark.
• Grupo Esteve: Privately-held Spanish pharmaceutical company with prescription, API manufacturing, and fine chemicals divisions. Comparable in private ownership structure, Spanish market leadership, and multi-therapeutic branded portfolio. Larger overall scale but similar business architecture.

Broad incumbents

• GSK: Global pharmaceutical leader in respiratory medicines (Advair, Trelegy) with extensive inhaler technology. Directly competes with Luforbec in the Spanish asthma/COPD market and represents the established respiratory incumbent that ERN's Lupin partnership positions it against.
• Bayer: Global pharmaceutical company with broad prescription and consumer health portfolio. Overlaps with ERN in corticosteroids, fluid therapy, and OTC categories. Represents the competitive backdrop for ERN's hospital and self-care products.
• Sanofi: Global pharmaceutical giant with significant pediatric portfolio and Spanish market presence through Sanofi-Aventis. Overlaps with ERN in pediatric formulations, fluid therapy, and respiratory categories, though operating at vastly larger scale across global markets.

Emerging players

• Meitheal Pharmaceuticals: US-based specialty pharmaceutical company commercializing injectable generics and biosimilars. Direct US licensing partner for Contepo (IV fosfomycin) and therefore highly relevant for understanding ERN's US market trajectory and competitive dynamics in the US injectable antibiotic space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios ERN